PAWC
CGTX icon

P.A.W. Capital’s Cognition Therapeutics CGTX Stock Holding History

P.A.W. Capital’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,000
Closed -$190K – 30
2022
Q3 		$190K Sell
100,000
-35,000
-26% -$72.9K 0.28% 55
2022
Q2 		$285K Buy
135,000
+15,000
+13% +$38.8K 0.41% 53
2022
Q1 		$330K Buy
120,000
+20,000
+20% +$77.1K 0.34% 58
2021
Q4 		$632K Buy
+100,000
New +$975K 0.58% 57

Other funds holding CGTX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

P.A.W. Capital's CGTX Position: Q4 2022 in Review

P.A.W. Capital sold out of Cognition Therapeutics (CGTX) in Q4 2022, closing a stake of 100,000 shares — an estimated $190K sold.

P.A.W. Capital first reported a position in CGTX in Q4 2021 and held it in 4 quarters. The position peaked at $632K in Q4 2021. 34 funds tracked by Wall St. Rank hold CGTX as of Q4 2022.

  • P.A.W. Capital reported no remaining Cognition Therapeutics position as of Q4 2022 after selling out during the quarter.
  • P.A.W. Capital sold 100,000 Cognition Therapeutics shares in Q4 2022, an estimated $190K.
  • P.A.W. Capital first reported a position in Cognition Therapeutics in Q4 2021 and held it in 4 quarters.
  • P.A.W. Capital's Cognition Therapeutics position peaked at $632K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2022.

Based on P.A.W. Capital's 13F filing for Q4 2022, filed 14 Feb 2023.